It’s that time of the year when the annual meeting of the American Society of Clinical Oncology (ASCO) hurtles around with alarming speed out of nowhere and everyone in Pharmaland goes, “ASCO, what already? Is it really June?!” Suddenly the month becomes the focus for many frantic hives of activity.
The last two years have seen some unprecedented changes in new therapies emerging to treat several different tumour types, both liquid and solid. One of the new trends that has begun to emerge is the new class of immunotherapy agents called checkpoint regulator inhibitors. These include:
- CTLA-4 (ipilimumab)